Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligomerization nucleic acid composition for preventing or treating canine distemper and application thereof

An oligonucleotide and DNA molecule technology, applied in the field of oligonucleotide combination for the prevention or treatment of canine distemper, can solve the problems of lax management, difficulty in general vaccines having broad applicability, and decreased vaccine antibody titers, etc.

Inactive Publication Date: 2018-04-06
SHANGHAI GENEPHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the genetic variation of CDV, it is difficult for ordinary vaccines to be widely applicable
Moreover, the current management of CDV vaccines is not rigorous, the quality of vaccines on the market varies, and the vaccine strains used by various manufacturers are not the same. After the above situation, it will further lead to a rapid decline in the vaccine antibody titer and a decrease in antigen specificity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligomerization nucleic acid composition for preventing or treating canine distemper and application thereof
  • Oligomerization nucleic acid composition for preventing or treating canine distemper and application thereof
  • Oligomerization nucleic acid composition for preventing or treating canine distemper and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] The preparation of the oligonucleotide of embodiment 1, modification

[0089] The sense strand and antisense strand shown in Table 1 were synthesized by Shanghai Gemma Pharmaceutical Technology Co., Ltd.

[0090] Dilute the sense strand with deionized water to obtain a sense strand dilution. Dilute the antisense strand with deionized water to obtain antisense strand dilution. Take the dilution solution of the sense strand and the corresponding dilution solution of the antisense strand, and perform annealing reaction to form oligonucleotides. The 3' end of each oligonucleotide is subjected to cholesterol modification, and the 5' end is subjected to phosphorylation modification to obtain a modified oligonucleotide.

[0091] A total of 28 oligonucleotides shown in Table 1 were prepared in this embodiment. A, G, C and U in each oligonucleotide represent adenine ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide and uracil ribonucleotide in sequence, and T re...

Embodiment 2

[0095] The modified oligonucleotide prepared by embodiment 2, embodiment 1 is on the impact of the relative expression of N gene, F gene and H gene of CDV

[0096] 1. Construction of recombinant plasmids

[0097] 1. Construction of recombinant plasmid pCDNA3.1-N

[0098] (1) According to the nucleotide sequence of the N gene of CDV (Sequence ID: gb|EU409838.1| or Genebank: EU409838.1), designed and synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd. as shown in sequence 49 in the sequence list DNA fragments. The 1st to 11th positions from the 5' end of sequence 49 are protective bases and the recognition sequence of restriction endonuclease HindⅢ, the 12th to 1583rd are the nucleotide sequence of the N gene, and the 1584th to 1594th are protective Base and recognition sequence of restriction endonuclease EcoRI.

[0099] (2) Digest the DNA fragment synthesized in step (1) with restriction endonuclease Hind III and EcoR I, and recover the digested product with a ...

Embodiment 3

[0155] The modified oligonucleotide prepared by embodiment 3 and embodiment 1 inhibits the replication of Vero cell virus infected with canine distemper attenuated CDV3-CL strain

[0156] 1. Preparation of Interfering Compositions

[0157] 1. Interfering composition 1

[0158] Take the N gene-119, N gene-476, N gene-749, N gene-435 and N gene-927 prepared in Example 1 and mix them according to the molar ratio of 1:1:1:1:1 to obtain the interference combination Object 1.

[0159] 2. Interference composition 2

[0160] F gene-485, F gene-685, F gene-792 and F gene-1279 prepared in Example 1 were mixed according to a molar ratio of 1:1:1:1 to obtain interference composition 2.

[0161] 3. Interference composition 3

[0162] Hgene-416, Hgene-947, Hgene-1373, Hgene-1447 and Hgene-1664 prepared in Example 1 were mixed according to the molar ratio of 1:1:1:1:1 to obtain interference composition 3.

[0163] 4. Interference composition 4

[0164] The H gene-119, F gene-485 and H ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an oligomerization nucleic acid composition for preventing or treating canine distemper and application thereof. The application of the oligomerization nucleic acid compositionis any one as follows: (b1) inhibiting nucleic acid replication of canine distemper viruses; (b2) preparing medicines for treating canine distemper; (b3) inhibiting the growth of canine distemper viruses; (b4) preparing medicines for preventing canine distemper occurrence or propagation; and (b5) promoting death or deactivation of canine distemper viruses. Tests show that the oligomerization nucleic acid composition disclosed by the invention is capable of inhibiting replication of canine distemper viruses and has significant application values for preventing or treating canine distemper.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an oligonucleotide combination for preventing or treating canine distemper and its application. Background technique [0002] Canine distemper is an acute, highly contagious disease caused by canine distemper virus (CDV). It has reached all 8 families of Carnivora, Artiodactyla Suidae, Primates Rhesus and Pinniped Sealidae and other animals, and there is a trend of continuous expansion. CDV nucleic acid has also been detected in human osteitis deformans patients molecular. CDV is a negative-sense, single-strand, non-segmented RNA virus. It belongs to the Paramyxoviridae Morbillivirus genus in taxonomy with measles virus, rinderpest virus, and seal virus. Its genome length is about 16 kb. Studies have shown that the fusion protein (encoded by the F gene) and hemagglutinin protein (encoded by the H gene) of CDV are the main target antigens of the host immune system and one of the impor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113C12N15/11A61K48/00A61K31/7088A61P31/14
CPCA61K31/7088C12N15/1131C12N2310/10C12N2310/321
Inventor 董长贵李琴张佩琢杜永华
Owner SHANGHAI GENEPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com